2 completed, 2 recruiting, 1 active not recruiting, 1 suspended. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Suspended 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Dwight Owen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | Dwight Owen | 24 | 2024-12-31 | 2026-09-18 |
| PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Recruiting | Dwight Owen | 30 | 2022-11-21 | 2026-02-06 |
| Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer Atezolizumab, Temozolomide - Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 2 | Recruiting | Dwight Owen | 56 | 2022-01-26 | 2026-04-08 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Tretinoin - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | Dwight Owen | 18 | 2021-10-18 | 2026-07-20 |
| Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Nivolumab, Temozolomide - Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma | Phase 2 | Completed | Dwight Owen | 55 | 2018-12-31 | 2026-08-18 |
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate - Thymic Carcinoma | Phase 2 | Active not recruiting | Dwight Owen | 9 | 2018-06-19 | 2026-08-06 |
Lung Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (3) · Small Cell Lung Carcinoma (2) · Carcinoma, Neuroendocrine (1) · Neuroendocrine Tumors (1) · Thymoma (1)
atezolizumab (3) · Nivolumab (2) · Temozolomide (2) · HhAntag691 (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Sunitinib (1) · Tretinoin (1) · pembrolizumab (1)
United States (6)
Dwight H Owen, MD (2) · Dwight H Owen, MD, MS, FACP (1)
R01CA248741 (1)